A Study（Phase I）of GS3-007a Dry Suspension in Healthy Chinese Adults

Phase 1 Recruiting 32 enrolled Changchun GeneScience Pharmaceutical Co., Ltd.

RandomizedParallel-groupTriple-blindTreatment

Summary

This study consists of two parts: the first part is a single-dose escalating（SAD） and food effect （FE）study, and the second part is a multiple-dose (14-day) escalating(MAD) study. Both phases are designed as randomized, double-blind, dose-escalation, placebo-controlled clinical studies.

Timeline

Start: 2026-01-07
Primary completion: 2026-06
Completion: 2026-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GS3-007a	Unknown	—	Oral

Indications

No indication recorded.